Key result
High TRS 2°P score predicts a ~20-fold higher risk of recurrent CV events post-NSTEMI.
Why the study?
Patients surviving NSTEMI face heightened risk of recurrent cardiovascular events, but data on long-term secondary atherothrombotic risk stratification are limited.
Does the TIMI Risk Score for Secondary Prevention (TRS 2°P) predict recurrent cardiovascular events in post-NSTEMI patients?
Observational (n=891)
No
Does the TIMI Risk Score for Secondary Prevention (TRS 2°P) predict recurrent cardiovascular events in post-NSTEMI patients?
Effect estimate: HR 20.18 (95% CI 4.85 to 84.05)
Absolute Event Rate: 47.4% vs 1.6%
p-value: p=<0.001
The TRS 2°P score strongly predicts recurrent cardiovascular events in a real-world cohort of post-NSTEMI patients, which may help guide secondary prevention strategies.
TRS 2°P may support risk stratification post-NSTEMI; leaves open whether score-guided therapy improves outcomes.
BACKGROUND: Patients who survive non-ST-elevation myocardial infarction (NSTEMI) are at heightened risk of recurrent cardiovascular events. Data on long-term secondary atherothrombotic risk stratification are limited. OBJECTIVES: To stratify post-NSTEMI patients for risk of recurrent cardiovascular events to maximise benefit from aggressive secondary prevention strategies using the TIMI Risk Score for Secondary Prevention (TRS 2°P) score in a real-world cohort of NSTEMI patients. METHODS AND RESULTS: This was a single-centre observational study of 891 post-NSTEMI patients (73.7 ± 12.7 years; male: 54.2%). The TRS 2°P is a nine-point risk stratification tool to predict cardiovascular events in patients with established cardiovascular disease. The primary outcome was a composite endpoint of cardiovascular death, non-fatal MI and non-fatal ischaemic stroke. After a median follow-up of 31 months (IQR: 11.4 - 60.2), 281 patients (31.5%) had developed a primary outcome (13.3%/year) including 196 cardiovascular deaths, 94 non-fatal MIs and 22 non-fatal strokes. The TRS 2°P score was strongly associated with the primary outcome. The annual incidence of primary composite endpoint for patients with TRS 2°P score =0 was 1.6%, and increased progressively to 47.4% for those with a TRS 2°P score ≥6 (HR: 20.18, 95% CI: 4.85 to 84.05, p<0.001). Similar associations were also observed between the TRS 2°P score and cardiovascular death and MI (fatal and non-fatal), but not non-fatal ischaemic stroke. CONCLUSION: The TRS 2°P score stratified post-NSTEMI patients for risk of future cardiovascular events and potentially help guide the selection of more aggressive secondary prevention therapy.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2019) conducted an observational in post-non-ST-elevation myocardial infarction (NSTEMI) (n=891). TIMI Risk Score for Secondary Prevention (TRS 2°P) vs. TRS 2°P score = 0 vs ≥6 was evaluated on composite endpoint of cardiovascular death, non-fatal MI and non-fatal ischaemic stroke (HR 20.18, 95% CI 4.85 to 84.05, p=<0.001). The TRS 2°P score strongly predicted recurrent cardiovascular events in post-NSTEMI patients, with annual incidence increasing from 1.6% for a score of 0 to 47.4% for a score ≥6 (HR 20.18; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: